<DOC>
	<DOCNO>NCT00002372</DOCNO>
	<brief_summary>To determine steady-state pharmacokinetics 141W94 combination saquinavir , indinavir nelfinavir multiple oral dosing . To determine steady-state pharmacokinetics saquinavir , indinavir , nelfinavir combination 141W94 multiple oral dosing . To assess safety tolerability multiple dose 141W94 combined saquinavir , indinavir nelfinavir .</brief_summary>
	<brief_title>A Study 141W94 Combination With Other Anti-HIV Drugs</brief_title>
	<detailed_description>Patients randomize receive open label 141W94 combination saquinavir , indinavir nelfinavir . The randomized phase precede single dose pharmacokinetic interaction study 141W94 indinavir 12 patient . Data single dose investigation use determine dose indinavir use randomized phase .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed provide used caution : Medications may interact CYP3A4 ( either substrate , inhibitor inducer enzyme ) use caution . Patients must : Documented HIV infection . CD4+ cell count &gt; = 200 cells/mm3 . 1 . Anticipated need treatment cytotoxic chemotherapeutic agent within study time period . Treatment immunomodulating agent . Medications administer 141W94 : Terfenadine . Astemizole . Cisapride . Triazolam . Midazolam . Ergotamine/Dihydroergotaminecontaining regimen . Antiretroviral drug . Vitamin E supplement . Other experimental agent . Anticipated need radiation therapy within study time period . 1 . Prior protease inhibitor . Antiretroviral therapy within 2 week prior entry . Treatment cytotoxic chemotherapeutic agent within 4 week prior entry . Radiation therapy within 4 week prior entry . Current alcohol illicit drug use , opinion investigator , may interfere patient 's ability comply dose protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>VX 478</keyword>
</DOC>